6th October 2022
We are pleased to announce the inauguration of three new Supervisory Board members following their recent confirmation at the EIT Health Partner Assembly in September.
The EIT Health Supervisory Board plays a vital role in our organisation, helping us drive healthcare innovation across Europe. The Board oversees the activities of EIT Health and monitors the definition, approval, and fulfilment of the 2021-27 Strategic Agenda. The Board also appoints EIT Health’s CEO and COO, supervises their work and discusses and approves strategic decisions of EIT Health’s Management team. Meet our new Board members:
Guy Villax, Board Member, Hovione
Guy Villax has several non-executive roles in a number of organisations related to health, pharmaceuticals and innovation. He is a board member of Hovione, a company he led for 25 years, Chair of the Advisory Board of the Portuguese National Innovation Agency (ANI), Chair of the Board of the Health Cluster Portugal, member of Portugal’s National Council on Science, Technology and Innovation, and now a member of the Supervisory Board of EIT Health.
Guy has a degree in Accounting and Financial Management from the University College in Buckingham, UK. He is fluent in English, French, Portuguese, Italian and Spanish.
Lucas Scherdel, Managing Director, DayOne
Lucas Scherdel is the Managing Director of Switzerland’s leading health tech accelerator, DayOne and Director of Health Innovation for the Economic Promotion Agency of the life science capital of the Basel Area. He has spent over a decade leading health innovation initiatives for institutions such as the NHS, WHO and World Economic Forum.
He holds degrees in Neuroscience, Philosophy, Politics and Economics of Health and was named on the Forbes List – Europe – 30 Under 30 for Science & Healthcare for his achievements in March, 2020.
Ariane Galaup Paci, Director for Research, Leem
Ariane Galaup Paci holds two decades of experience in research and development. Her current position enhances her expertise in research and development of the pharmaceutical industry sector, preparing health innovation and research strategy of the sector, contributing to the French transformation for new developments and accelerating health innovation access for patients in France and Europe.
Please join us in congratulating our new Board members. Find out more about EIT Health and its governance structure.
NALA.care joins forces with La Roche-Posay
Discover how the partnership will benefit patients
Leuko closes €5M Series A round
Learn more about Leuko and its achievements
EIT Health appoints three new Supervisory Board members
Join us in welcoming our new Board members